Please login to the form below

Not currently logged in
Email:
Password:

eribulin

This page shows the latest eribulin news and features for those working in and with pharma, biotech and healthcare.

Keytruda monotherapy fails in triple negative breast cancer

Keytruda monotherapy fails in triple negative breast cancer

By contrast, Merck &Co’s phase 3 Keynote-119 trial evaluated Keytruda as a monotherapy for the second or third-line treatment compared to chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine).

Latest news

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    In the OLYMPIAD trial, Lynparza achieved a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared to standard chemotherapy (with capecitabine, vinorelbine or eribulin).

  • NICE set to reject wider use of Eisai’s Halaven NICE set to reject wider use of Eisai’s Halaven

    Issues draft guidance recommending against second-line use in breast cancer. Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to ... According to the appraisal committee “it’s not clear

  • AZ's Lynparza shows PARP inhibitor potential in breast cancer AZ's Lynparza shows PARP inhibitor potential in breast cancer

    Lynparza (olaparib) significantly improved progression-free survival (PFS) in women with HER2-negative metastatic breast cancer with a germline BRCA mutation, when compared with standard therapy with capecitabine, vinorelbine or eribulin

  • AZ moves closer to Lynparza filing in breast cancer AZ moves closer to Lynparza filing in breast cancer

    Compared to standard chemotherapy with capecitabine, vinorelbine or eribulin, Lynparza achieved a "statistically-significant and clinically-meaningful" improvement in progression-free survival (PFS) in the OLYMPIAD trial, said the company, although

  • NICE backs Eisai's Halaven for breast cancer NICE backs Eisai's Halaven for breast cancer

    The UK health technology assessment agency has approved Halaven (eribulin) for routine treatment of patients with locally advanced or metastatic breast cancer that has spread after two prior chemotherapy regimens. ... metastatic breast cancer in England

More from news
Approximately 4 fully matching, plus 28 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics